Hydrocodone bitartrate

Results demonstrated statistically significant pain reduction, rapid onset of analgesia, and opioid-sparing potential of investigational selective Na v 1.8 inhibitor LTG-001 Marks only the second original research publication in the New England Journal of Medicine reporting clinical results for a novel drug for acute pain in the last 15 years THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Latigo Biotherapeutics, Inc. (Latigo), a clinical-stage biopharmaceutical company developing innovative non-opioid pain medicines, today announced the publication of positive results from the abdominoplasty clinical trial evaluating LTG-001 for the treatment of moderate-to-severe acute postoperative pain as an original research article in the New England Journal of Medicine (NEJM). LTG-001 is an investigational selective Na v 1.8 inhibitor, part of a new class of non-opioid analgesics designed to selectively block the transmission of pain. The publication reports results from a large-scale, double-blind, randomized, placebo- and comparator-controlled dose-ranging clinical trial evaluating LTG-001 versus placebo in adults with moderate-to-severe pain following abdominoplasty, a well-established postoperative pain model. The trial enrolled 343 participants who reported moderate or severe pain after surgery. The patients were randomized 1:1:1:1 to receive high-dose LTG-001 (450 mg loading dose followed by 300 mg every 12 hours), low-dose LTG-001 (300 mg loading dose followed by 150 mg every 12 hours), the opioid comparator, HB/APAP (commonly known as Vicodin; 5 mg hydrocodone bitartrate and 325 mg acetaminophen every 6 hours), or placebo. The study met its primary endpoint of the Summed Pain Intensity Difference over 48 hours (SPID48) versus placebo with high statistical significance and demonstrated rapid, clinically meaningful pain relief, favorable tolerability and opioid-sparing potential. ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); “This publication in the New England Journal of Medicine is a significant milestone for LTG-001,” said Neil Singla, M.D., chief medical officer of Latigo. “The publication of these findings adds to the growing scientific understanding of non-opioid approaches to pain management and comes at a time when there is broad recognition of the need for additional treatment options in the context of the ongoing opioid crisis.” “From a clinical perspective, the published LTG-001 results in moderate-to-severe pain following abdominoplasty represent an important development in the treatment of acute pain, with the highest analgesic effect reported in a published industry-sponsored abdominoplasty trial,” said Harold Minkowitz, M.D, of ERG Research, an anesthesiologist and leading investigator who has been involved in more than 300 clinical trials in pain. “While opioids have historically been among the most effective options for treating acute pain, their associated risks underscore the importance of continued research into non-opioid approaches. These published results of LTG-001 add to the growing body of evidence supporting the investigation of novel, non-opioid mechanisms for pain management at a time when there remains significant focus on addressing the public health impact of opioid use.” Key findings reported in NEJM from the abdominoplasty trial include: Primary endpoint achieved, with high-dose LTG-001 achieving statistically significant improvement in Summed Pain Intensity Difference over 48 hours (SPID48) versus placebo Patients receiving high-dose LTG-001 achieved a SPID48 of 62.1, representing the highest analgesic effect reported for any analgesic tested in the abdominoplasty pain model to our knowledge High-dose LTG-001 showed an approximately 50% greater analgesic effect than Vicodin, the opioid comparator in the trial Median onset of meaningful pain relief was approximately 52 minutes for high-dose LTG-001 and 83 minutes for the opioid comparator in the trial 52.3% of patients receiving high-dose LTG-001 remained opioid-free throughout the 48-hour treatment period. In the placebo group, only 22.1% remained opioid-free Dose response observed with low-dose LTG-001 (300 mg loading followed by 150 mg every 12 hours) also demonstrated statistically significant improvement versus placebo (SPID48 of 37.8) roughly comparable to the effect of the opioid comparator in the trial Treatment-emergent adverse events were mostly mild to moderate, and overall adverse event levels were below those observed in the placebo arm “The publication of the LTG-001 results in The New England Journal of Medicine recognizes the significance of these findings and marks an important milestone for Latigo,” said Nima Farzan, chief executive officer of Latigo. “We are honored to have these data published in such a prestigious journal, reflecting the quality of the science and the dedication of the patients, investigators, and Latigo team who made this achievement possible.” About Latigo Biotherapeutics Latigo Biotherapeutics is a private clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction, with the goal to provide effective, rapid-acting pain relief. Latigo is supported by leading investors, including Westlake Village BioPartners, Foresite Capital, 5AM Ventures, and Blue Owl Capital. Latigo’s lead program is LTG-001, an oral, selective Na v 1.8 inhibitor in development to treat acute pain. For more information, please visit or follow us on LinkedIn . Contacts Investor Contact: Neha Krishnamohan Latigo Biotherapeutics, Inc. ir@latigobio.com Media Contact: Kathy Vincent Greig Communications, Inc. kathy@greigcommunications.com

A new medically supervised outpatient detox center opens in Jacksonville, giving Northeast Florida adults a clinical path to withdrawal care that fits life. Serenus Outpatient Detox provides safe, evidence-based outpatient detox services, letting clients receive the medical and clinical support needed while staying connected to family, work, and recovery.” — Donnie Huston, Executive Director at Serenus Outpatient Detox. JACKSONVILLE, FL, UNITED STATES, June 29, 2026 / EINPresswire.com / -- Serenus Outpatient Detox is now open in Jacksonville, Florida, bringing a new standard of medically supervised outpatient detox to Northeast Florida. Located at 11555 Central Pkwy, Suite 202, Jacksonville, FL 32224, the program provides structured, physician-overseen withdrawal care for adults seeking recovery from alcohol, opioids, benzodiazepines, stimulants, and other substances, without requiring an inpatient admission or residential stay. The program is open Monday through Friday, 7 AM to 7 PM; Saturday and Sunday, 8 AM to 2 PM, and is now accepting patients. Filling a Critical Gap in Jacksonville Drug & Alcohol Detox Serenus Outpatient Detox was founded by clinicians, counselors, and recovery advocates who identified a persistent gap in Northeast Florida's behavioral health landscape: people who needed safe, effective, medically supervised withdrawal care, but had work obligations, family responsibilities, or other circumstances that made inpatient detox impractical or simply not the right fit. Unlike residential treatment programs, Serenus provides medical detox in Jacksonville in an outpatient setting for individuals who need safe, evidence-based withdrawal care with daily medical monitoring, while continuing to live at home, work, and remain connected to their families, support systems, and everyday responsibilities. Clients visit the center daily for approximately two hours per visit. During each visit, nursing staff monitor vitals and manage withdrawal symptoms using FDA-approved medications tailored to each individual's history and medical needs. Clients also meet with a peer support specialist every day, receive weekly one-on-one sessions with a licensed substance use counselor, and participate in group programming centered on recovery, not just symptom management. Every detox protocol at Serenus is fully individualized. The clinical team builds each client's plan around their specific substance history, medical background, and recovery goals. A Full Range of Outpatient Detox Services The Jacksonville drug and alcohol detox program at Serenus treats withdrawal from a wide range of substances, including: - Alcohol, one of the most medically complex withdrawals and one the Serenus team is specifically equipped to manage safely - Opioids, including heroin, fentanyl, oxycodone, and hydrocodone - Benzodiazepines, including Xanax, Valium, Klonopin, and Ativan - Stimulants, including cocaine and methamphetamine - Prescription medications and other dependency-forming drugs Medication-assisted treatment options, including Vivitrol, are available on-site. The program also accommodates clients who are managing existing medication prescriptions from outside providers. From the first day of treatment, the Serenus team works alongside each client to develop a concrete aftercare plan, ensuring the right next step is identified and in place before the client completes the program. Serving Jacksonville & Northeast Florida Located in the Southside area of Jacksonville near Central Parkway, Serenus Outpatient Detox Jacksonville FL is accessible to individuals throughout Duval County and the broader Northeast Florida region, including Jacksonville Beach, Orange Park, Ponte Vedra, and surrounding communities. The program accepts most major insurance plans, and private-pay options are available. Serenus works closely with hospitals, primary care providers, therapists, non-profits, community partners, and behavioral health organizations throughout Northeast Florida. Providers and organizations interested in establishing a referral relationship are encouraged to reach out directly at 904-890-1442 or serenusdetox.com. For those seeking medical detox Jacksonville residents can rely on, Serenus offers a clinically rigorous, community-connected alternative to inpatient care. Grand Opening Open House: August 12 The Open House on August 12 will provide healthcare professionals, community partners, and members of the public an opportunity to tour the facility, meet the clinical team, and learn more about the medically supervised outpatient detox program at Serenus. Food and refreshments will also be provided. To RSVP for the August 12 open house, visit serenusdetox.com/open-house-rsvp. To learn more about outpatient detox Jacksonville FL services at Serenus, visit serenusdetox.com or call 904-890-1442. About Serenus Outpatient Detox is a medically supervised outpatient detox center located in Jacksonville, Florida. The program provides individualized, clinically comprehensive withdrawal care for adults seeking recovery from alcohol, opioids, benzodiazepines, stimulants, and other substances, without the need for inpatient admission. Serenus is built on the belief that safe detox and real recovery should fit inside your life. Donald Huston Serenus Outpatient Detox +1 904-890-1442 donnie@serenusdetox.com Visit us on social media: LinkedIn Instagram Facebook Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.